Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 498-518

  Müller, Karin A L ^a,b   Chatterjee, Madhumita ^a   Rath, Dominik ^a   Geisler, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Antiplatelet agents; Atherosclerosis; Cytokines; Inflammation; Platelet physiology

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; C REACTIVE PROTEIN; CANGRELOR; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOPHILLIN A; INTEGRIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; RANTES; THROMBOCYTE FACTOR 4; TICAGRELOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VORAPAXAR; ANTIINFLAMMATORY AGENT; AUTACOID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; ACUTE CORONARY SYNDROME; ANIMAL; BLOOD; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION MEDIATORS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84940641465     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0947     Document Type: Article

References (192)

1. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489–495.
2. Weyrich AS, et al. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897–1905.
3. de Boer HC, et al. Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. Arterioscl Thromb Vasc Biol 2006; 26: 1653–1659.
4. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischaemic myocardium. Cardiovasc Res 2004; 61: 498–511.
5. Gawaz M, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75–85.
6. Ross R, et al. Platelets, macrophages, endothelium, and growth factors. Their effects upon cells and their possible roles in atherogenesis. Ann NY Acad Sci 1985; 454: 254–260.
7. Hawrylowicz CM, et al. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991; 174: 785–790.
8. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 612–616.
9. von Hundelshausen P, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772–1777.
10. Schober A, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523–1529.
11. Scheuerer B, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158–1166.
12. Sachais BS, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 3613–3622.
13. Pitsilos S, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 906: 1112–1120.
14. Nassar T, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 6187–6193.
15. Henn V, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591–594.
16. Gawaz M, et al. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378–3384.
17. Fernandez-Patron C, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and –2. Thromb Haemost 1999; 82: 1730–1735.
18. May AE, et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106: 2111–2117.
19. Nannizzi-Alaimo L, et al. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107: 1123–1128.
20. Bunting M, et al. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol 2002; 9: 30–35.
21. Danese S, et al. Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol 2007; 178: 6017–6022.
22. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nature Rev Immunol 2007; 7: 803–815.
23. Chatterjee M, et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 2011; 117: 3907–3911.
24. Stellos K, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117: 206–215.
25. Massberg S, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221–1233.
26. Stellos K, et al. Platelet aggregates-induced human CD34+ progenitor cell proliferation and differentiation to macrophages and foam cells is mediated by stromal cell derived factor 1 in vitro. Semin Thromb Hemost 2010; 36: 139–145.
27. Thelen M, Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio? J Neuroimmunol 2008; 198: 9–13.
28. Kraemer BF, et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). J Mol Med 2010; 88: 1277–1288.
29. Kraemer BF, et al. High shear flow induces migration of adherent human platelets. Platelets 2011; 22: 415–421.
30. Rath D, et al. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. Eur Heart J 2014; 35: 386–394.
31. Chatterjee M, et al. SDF-1alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. FASEB J 2014; 28: 2864–2878.
32. Chatterjee M, et al. Macrophage Migration Inhibitory Factor Limits Activation- Induced Apoptosis of Platelets via CXCR7-Dependent Akt Signaling. Circ Res 2014; 115: 939–949.
33. Zernecke A, et al. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117: 1594–1602.
34. Strussmann T, et al. Platelets are a previously unrecognised source of MIF. Thromb Haemost 2013; 110: 1004–1013.
35. Muller II, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PloS one 2012; 7: e38376.
36. Seizer P, et al. Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases. Cardiovasc Res 2014; 102: 17–23.
37. Wang L, et al. Cyclophilin A is an important mediator of platelet function by regulating integrin alphaIIbbeta3 bidirectional signalling. Thromb Haemost 2014; 111: 873–882.
38. Elvers M, et al. Intracellular cyclophilin A is an important Ca(2+) regulator in platelets and critically involved in arterial thrombus formation. Blood 2012; 120: 1317–1326.
39. Coppinger JA, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096–2104.
40. Eisenhardt SU, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localises inflammation to atherosclerotic plaques. Circ Res 2009; 105: 128–137.
41. Venugopal SK, et al. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/ autocrine effects. Am J Pathol 2005; 166: 1265–1271.
42. Tsimikas S, et al. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006; 47 (8 Suppl): C19–31.
43. Koenig W, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–242.
44. Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
45. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003; 107: 370–371.
46. Jialal I, et al. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6–11.
47. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805–1812.
48. Devaraj S, et al. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006; 291: H1170–1176.
49. Inoue T, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005; 46: 239–245.
50. Meuwissen M, et al. Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 2006; 59: 196–201.
51. Yasojima K, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. AmJ Pathol 2001; 158: 1039–1051.
52. Ji SR, et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 2007; 21: 284–294.
53. Khreiss T, et al. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004; 109: 2016–2022.
54. Muller K, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256–262.
55. Angiolillo DJ, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780–784.
56. Khreiss T, et al. Loss of pentameric symmetry in C-reactive protein induces interleukin- 8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 2005; 97: 690–697.
57. Zouki C, et al. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 2001; 167: 5355–5361.
58. Singh U, et al. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscl Thromb Vasc Biol 2006; 26: 2469–2475.
59. Khreiss T, et al. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110: 2713–2720.
60. Teupser D, et al. No reduction of atherosclerosis in C-reactive protein (CRP)- deficient mice. J Biol Chem 2011; 286: 6272–6279.
61. Simon LM, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014; 123: e37–45.
62. Dangwal S, Thum T. MicroRNAs in platelet biogenesis and function. Thromb Haemost 2012; 108: 599–604.
63. Laffont B, et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 2013; 122: 253–261.
64. Gatsiou A, et al. MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation. Curr Vasc Pharmacol 2012; 10: 524–531.
65. Stakos DA, et al. Platelet microRNAs: From platelet biology to possible disease biomarkers and therapeutic targets. Platelets 2013; 24: 579–589.
66. Kondkar AA, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8: 369–378.
67. Osman A, Falker K. Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets 2011; 22: 433–441.
68. Sondermeijer BM, et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PloS one 2011; 6: e25946.
69. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482–2494.
70. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr- Pharm Design 2006; 12: 1255–1259.
71. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922–2932.
72. Panes O, et al. Human platelets synthesize and express functional tissue factor. Blood 2007; 109: 5242–5250.
73. Brogren H, et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104: 3943–3948.
74. Rinder HM, et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78: 1730–1737.
75. Christersson C, et al. Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of Lyn and is inhibited by IL10. J Thromb Haemost 2008; 6: 986–994.
76. Elstad MR, et al. P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. J Immunol 1995; 155: 2109–2122.
77. Weyrich AS, et al. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009; 7: 241–246.
78. Boilard E, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580–583.
79. Woo JS, et al. Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy. Am J Cardiol 2014; 113: 786–792.
80. Antonino MJ, et al. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009; 103: 1546–1550.
81. Weber C, et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914–1917.
82. Fontana P, et al. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res 2014; 7: 29–38.
83. Otto GP, et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 2013; 24: 480–485.
84. Birnbaum Y, et al. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostagland Other Lipid Med 2007; 83: 89–98.
85. Birnbaum Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114: 929–935.
86. Passacquale G, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PloS one 2011; 6: e25595.
87. Machado FS, et al. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. J Exp Med 2008; 205: 1077–1086.
88. Javeed A, et al. Aspirin significantly decreases the nonopsonic phagocytosis and immunogenicity of macrophages in mice. Inflam Res 2011; 60: 389–398.
89. Ridker PM, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979.
90. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321: 129–135.
91. Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
92. Bartolucci AA, et al. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796–1801.
93. Meade T. Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. Handb Exp Pharmacol 2012; 210: 565–605.
94. Verheugt FW. The role of the cardiologist in the primary prevention of cardiovascular disease with aspirin. J Am Coll Cardiol 2015; 65: 122–124.
95. Brotons C, et al. A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? Am J Cardiovasc Drugs 2014; Epub ahead of print.
96. Pasche B, et al. Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol 2014; 41: 397–401.
97. Ikonomidis I, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793–798.
98. Chen YG, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–36.
99. Solheim S, et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003; 92: 843–845.
100. Solheim S, et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660–664.
101. Li N, et al. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165–170.
102. Iyengar S, Rabbani LE. Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. J Thromb Thrombol 2009; 27: 300–306.
103. Palabrica T, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848–851.
104. Klinkhardt U, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Therap 2003; 73: 232–241.
105. Klinkhardt U, et al. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Therap 2002; 71: 176–185.
106. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982–1988.
107. Azar RR, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521 e1–e4.
108. Vavuranakis M, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Therap 2006; 28: 860–871.
109. Quinn MJ, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679–684.
110. Harding SA, et al. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006; 92: 1335–1337.
111. Sabatine MS, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–1189.
112. Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.
113. Bellemain-Appaix A, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Am Med Assoc 2012; 308: 2507–2516.
114. Mehta SR, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–533.
115. Dibra A, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114: 715–722.
116. Toutouzas K, et al. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004; 25: 1679–1687.
117. Gurbel PA, et al. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006; 48: 2186–2191.
118. Chew DP, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88: 672–674.
119. Bhatt DL, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625–628.
120. Meune C, et al. Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. Eur J Heart Fail 2007; 9: 197–201.
121. Willerson JT, et al. PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Texas Heart Inst J 2009; 36: 530–539.
122. Wang L, et al. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 5: 16.
123. Wihlborg AK, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscl Thromb Vasc Biol 2004; 24: 1810–1815.
124. Ben Addi A, et al. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol 2010; 185: 5900–5906.
125. Liverani E, et al. LPS-induced systemic inflammation is more severe in P2Y12 null mice. J Leukocyte Biol 2014; 95: 313–323.
126. Storey RF, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014; 25: 517–525.
127. Husted S, et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010; 33: 206–212.
128. Bonello L, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014; 63: 872–877.
129. Armstrong D, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014; 19: 209–219.
130. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukocyte Biol 2008; 83: 447–455.
131. Hasko G, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Rev Drug Discov 2008; 7: 759–770.
132. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33–39.
133. Rahman M, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets 2014; 25: 257–263.
134. Grzesk G, et al. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res 2012; 130: 65–69.
135. Grzesk G, et al. High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. BioMed Res Intern 2013; 2013: 928271.
136. Tunjungputri RN, et al. Differential effects of platelets and platelet inhibition by ticagrelor on TLR2– and TLR4-mediated inflammatory responses. Thromb Haemost 2015; 113: 1035–1045.
137. Frelinger AL, 3rd, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 6: 359–365.
138. Totani L, et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost 2012; 107: 1130–1140.
139. Frelinger AL, 3rd, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192–200.
140. Judge HM, et al. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008; 19: 125–133.
141. Serebruany VL, et al. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82: 404–410.
142. Braun OO, et al. Greater reduction of platelet activation markers and plateletmonocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626–633.
143. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.
144. Liverani E, et al. Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Therap 2013; 344: 231–243.
145. Mylotte D, et al. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011; 9: 24–32.
146. Ho PM, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. J Am Med Assoc 2008; 299: 532–539.
147. Wykrzykowska JJ, et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombol 2009; 28: 410–417.
148. Obradovic S, et al. Men with Lower HDL Cholesterol Levels have Significant Increment of Soluble CD40 Ligand and High-sensitivity CRP Levels Following the Cessation of Long-term Clopidogrel Therapy. J Atheroscl Thromb 2014; Epub ahead of print.
149. Sambu N, et al. Clopidogrel withdrawal: is there a „rebound“ phenomenon? Thromb Haemost 2011; 105: 211–220.
150. Hobson AR, et al. Effects of clopidogrel on „aspirin specific“ pathways of platelet inhibition. Platelets 2009; 20: 386–390.
151. Armstrong PC, et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2010; 8: 613–615.
152. Shankar H, et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006; 4: 638–647.
153. Frelinger AL, 3rd, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1– and cyclooxygenase- 2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888–2896.
154. Sibbing D, et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010; 55: 558–565.
155. Fiedler KA, et al. Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION. Thromb Haemost 2014; 111: 1041–1049.
156. Garratt KN, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberte paclitaxel-eluting coronary stent placement. Circulation 2015; 131: 62–73.
157. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombol 2003; 15: 71–80.
158. Mascelli MA, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680–1688.
159. Kereiakes DJ. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function. Rev Cardiovasc Med 2006; 7 (Suppl 4): S3–11.
160. Boersma E, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189–198.
161. Lincoff AM, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163–167.
162. James SK, et al. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. Am Heart J 2004; 147: 267–274.
163. Steinhubl SR, et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113–122.
164. Ercan E, et al. Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris. Thromb J 2004; 2: 4.
165. Akbulut M, et al. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions. Curr Med Res Opin 2004; 20: 1759–1767.
166. Bhatt DL, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330–2341.
167. Ueno M, et al. Update on the clinical development of cangrelor. Exp Rev Cardiovasc Ther 2010; 8: 1069–1077.
168. Judge HM, et al. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 2005; 16: 398–407.
169. Jones WS, et al. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J 2014; 168: 588–596.
170. Scirica BM, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 2012; 380: 1317–1324.
171. Storey RF, et al. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost 2014; 111: 883–891.
172. O’Donoghue ML, et al. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombol 2012; 34: 36–43.
173. Rao AK, et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738–743.
174. Husted S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–1047.
175. Pels K, et al. Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factorkappaB and activator protein 1 activation in pigs. Eur J Clin Invest 2009; 39: 174–182.
176. Salanova B, et al. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/ IIIa) receptors cooperate in NF-kappaB activation of human neutrophils. J Biol Chem 2007; 282: 27960–27969.
177. Molero L, et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischaemic coronary artery. Br J Pharmacol 2005; 146: 419–424.
178. Bhatt DL, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–1988.
179. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.
180. Obi C, et al. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscl Thromb Vasc Biol 2009; 29: 1271–1276.
181. Coppinger JA, et al. Moderation of the platelet releasate response by aspirin. Blood 2007; 109: 4786–4792.
182. Voora D, et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol 2013; 62: 1267–1276.
183. Vivekananthan DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358–360.
184. Montalescot G, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931–938.
185. Heitzer T, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscl Thromb Vasc Biol 2006; 26: 1648–1652.
186. Merino A, et al. Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the –174 G/C IL-6 gene polymorphism. Am J Cardiol 2004; 94: 1300–1303.
187. Welt FG, et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Intervent 2004; 61: 185–189.
188. Boilard E, et al. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012; 8: 534–542.
189. Langer HF, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012; 110: 1202–1210.
190. Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 910–919.
191. Bonaca MP, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791–1800.
192. Mauri L, et al.; DAPT Study Investigators.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–2166.